<DOC>
	<DOCNO>NCT02687828</DOCNO>
	<brief_summary>This study evaluate safety profile effectiveness adalimumab Korean intestinal Behcet 's disease ( BD ) patient routine clinical practice .</brief_summary>
	<brief_title>A Prospective , Mono-Country Multi-center Study Observe Safety Effectiveness Adalimumab KoREan Intestinal Behcet 's Disease ( BD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Behcet Syndrome</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subjects must adult &gt; = 19 year Subjects eligible treat adalimumab intestinal Behcet 's disease accordance approve label Korea Subjects provide write authorization form use/disclose personal health data prior participate study Subjects contraindicate antiTNF agent Female subject pregnant breast feed Subjects participate interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Safety</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Effectiveness</keyword>
	<keyword>AMORE study</keyword>
	<keyword>Intestinal Behcet 's disease ( BD )</keyword>
</DOC>